FOS and Sepsis: In the LP202195 + FOS group, there was a 42% reduction in the incidence of sepsis within the first 60 days after birth, compared to placebo, as well as reduced rates of culture-positive and culture-negative sepsis, and lower respiratory tract infections, compared to placebo (5).